Learn more

NOVARTIS INFLAMMASOME RES INC

Overview
  • Total Patents
    27
  • GoodIP Patent Rank
    59,372
  • Filing trend
    ⇧ 700.0%
About

NOVARTIS INFLAMMASOME RES INC has a total of 27 patent applications. It increased the IP activity by 700.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and Brazil. Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and biotechnology are AXYS PHARM INC, REDDY CHEMINOR INC and CONGENIA SRL.

Patent filings per year

Chart showing NOVARTIS INFLAMMASOME RES INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Katz Jason 24
#2 Shen Dong-Ming 23
#3 Ghosh Shomir 22
#4 Venkatraman Shankar 22
#5 Glick Gary 18
#6 Franchi Luigi 16
#7 Seidel Hans Martin 14
#8 Roush William 14
#9 Winkler David Guenther 13
#10 Opipari Jr Anthony William 11

Latest patents

Publication Filing date Title
WO2020154499A1 Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity
WO2020154321A1 Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 Gut-targeted nlrp3 antagonists and their use in therapy
WO2020102576A1 Compounds and compositions for treating conditions associated with nlrp activity
WO2020102574A1 The compounds and compositions for treating conditions associated with nlrp activity
WO2020102098A1 Compounds and compositions for treating conditions associated with nlrp activity
WO2020102100A1 Compounds and compositions for treating conditions associated with nlrp activity
WO2020086732A1 Compounds and compositions for treating conditions associated with nlrp activity
WO2020086728A1 Compounds and compositions for treating conditions associated with nlrp activity
WO2020010140A1 Nlrp modulators
WO2020010118A1 Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
EP3697758A1 Sulphonamides and compositions thereof for treating conditions associated with nlrp activity
EP3658538A1 Compounds and compositions for treating conditions associated with nlrp activity
KR20200032154A Compounds and compositions for treating conditions associated with NLRP activity